

Company name: NeuroKaire (GenetikaPlus Ltd) Website: <https://www.neurokaire.com/>

CEO name: Talia Cohen Solal

CATEGORY: Biotech

SESSIONS:

- Personalized Medicine; Navigating Strategic Pathways – Pharma or Payers or Both
- AI Meets Pharma: Building a Sustainable Value for Biotech AI innovation in Drug Development

- Executive Summary:

NeuroKaire is a precision medicine company for CNS, utilizing patient-derived neurons from pluripotent stem cells to predict medication response for treatment optimization and effective drug development. Leveraging this technology as a platform, NeuroKaire helps pharma companies' de-risk and improve success rates for new drug development. This past year we launched BrightKaire, a blood-based test to help patients suffering from depression.

- Core Technology

Our “brain in a dish” technology requires only a simple blood test to determine which antidepressant treatment is best suited for a patient using our innovative stem cell technology. We are able to combine this unique technology with patient genetics and patient history, bringing the predictive power of our platform to an unprecedented 79.3% accuracy.

- Product Profile

We have launched our first product, BrightKaire, and are now focusing on improving access and optimizing the platform. We are expanding our relationships with healthcare networks and providers to support market adoption and integration. We're advancing multiple pharma partnerships in 2025 to develop the platform application to Alzheimer's Disease. We will build our capacity through the remainder of this year.

- Business Strategy

Our business model is split between clinical lab tests and pharma partnerships. The former is focused on penetrating the market with our clinical lab test, which in turn, further develops our data asset and biobank for patient stratification. With partnerships, the data asset will be used to generate efficiencies and improve success rates in drug development via pharma partnerships.

- What's Next?

Expanding our relationships with more mental and behavioral health clinics across the US to help more patients suffering from depression as soon as possible. Continue to improve the quality and precision of our platform, especially with regards to the neuronal imaging analysis. Further develop our partnerships to achieve milestones for mutual success and expand to additional disease areas.